Regeneus partners with Australian Department of Defence to develop Sygenus for combat casualty care

Regeneus is excited to announce it is partnering with the Australian Department of Defence to develop its platform stem cell bioactive secretome technology Sygenus for combat casualty care. As part of the grant, Regeneus will receive $300k in funding to optimise the Sygenus formulation to treat combat casualties, including conducting Sygenus’ first in human study on pain.

Read the full announcement here.